Qingfei Zheng, Ph.D. is currently an Assistant Professor in the Borch Department of Medicinal Chemistry and Molecular Pharmacology (BMCMP) within the College of Pharmacy at Purdue University. Dr. Zheng started his independent academic research in 2021 as a tenure-track Assistant Professor in the College of Medicine at The Ohio State University and moved to Purdue in 2024. His lab applies multidisciplinary technologies (such as chemical biology, synthetic biology, biochemistry, medicinal chemistry, and biophysics approaches) towards studying novel protein post-translational modifications (PTMs), epigenetics, cancer metabolism, and tumor microbiome for the development of new personalized cancer therapies (especially immuno-oncology). For instance, his lab has developed a series of chemical biology tools and chemical proteomics approaches to study novel histone PTMs (e.g., glycation and monoaminylation) that are directly or indirectly induced by microbial metabolites. Moreover, utilizing these powerful chemical biology methodologies, Dr. Zheng and his colleagues have identified a number of previously unreported or unnamed PTMs on histones and uncovered their epigenetic functions in cancer development and treatment. Overall, his work has provided novel insights to understand the associations between the human microbiome metabolism and epigenetic regulations, thus facilitating the discovery of new drugs targeting these novel pathways.